

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alcumdria, Virginia 22313-1450
www.uspto.gov

| PPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO |
|-------------------------------------|----------------------------------|----------------------|-----------------------|-----------------|
| 09/978,403 | 10/16/2001 | Avi J. Ashkenazi | GNE.2630P1C17 | 4707 |
| 35489 | 7590 02/13/2004 | | EXAMINER | |
| HELLER EHRMAN WHITE & MCAULIFFE LLP | | | KEMMERER, ELIZABETH | |
| | EFIELD ROAD RK, CO 94025-3506 | | ART UNIT PAPER NUMBER | |
| | , , | | 1646 | |

DATE MAILED: 02/13/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | |
|---|---|--|--|
| 0.65 | 09/978,403 | ASHKENAZI ET AL. | |
| Office Action Summary | Examiner | Art Unit | |
| | Elizabeth C. Kemmerer, Ph.D. | 1646 | |
| The MAILING DATE of this communication app Period for Reply | ears on the cover sheet with the c | orrespondence address | |
| A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). | 36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE | sely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133). | |
| Status | | | |
| 1) Responsive to communication(s) filed on 22 Se | eptember 2003. | | |
| 2a) This action is FINAL . 2b) ☑ This | action is non-final. | | |
| 3) Since this application is in condition for allowar closed in accordance with the practice under E | · | | |
| Disposition of Claims | | | |
| 4) Claim(s) 58-63 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) 58-63 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or | wn from consideration. | | |
| Application Papers | | | |
| 9)⊠ The specification is objected to by the Examine | | | |
| 10) ☐ The drawing(s) filed on 16 October 2001 is/are: | | | |
| Applicant may not request that any objection to the | | i i | |
| Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex | • | | |
| Priority under 35 U.S.C. § 119 | | | |
| 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list | s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)). | on No ed in this National Stage | |
| Attachment(s) | ∆ □ 1=1====== 0 | (DTO 442) | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) | 4) Interview Summary Paper No(s)/Mail Da | • | |
| 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date | | atent Application (PTO-152) | |

DETAILED ACTION

Status of Application, Amendments, And/Or Claims

The preliminary amendments received 16 October 2001, 20 February 2002, 19 March 2002 and 03 September 2002 have been entered in full. Claims 1-57 are canceled. Claims 58-63 are under examination.

The sequence listing has been entered into the file.

Specification

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. See page 124, line 37. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

The deposit of biological organisms is considered by the Examiner to be necessary for enablement of the current invention (see MPEP Chapter 2400 and 37 C.F.R.§§1.801-1.809). Examiner acknowledges the deposit of organisms under accession number ATCC 209808 under terms of the Budapest Treaty on International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure in compliance with this requirement.

35 U.S.C. § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 09/978,403

Art Unit: 1646

Claims 58 and 63 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 58 recites an antibody that binds a particular sequence whereas claim 63 recites an antibody that specifically binds that sequence. Neither the specification nor the art clearly defines a distinction between the two, such that the different metes and bounds of the claims cannot be determined.

35 U.S.C. § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 58-63 are rejected under 35 U.S.C. 102(e) as being anticipated by Ruben et al. (US 2003/0050435 A1; effective filing date 6 July 1997).

Ruben et al teach an isolated polypeptide 100% identical to SEQ ID NO: 145 (see SEQ ID NO: 189 of Ruben et al., columns 245-246). Ruben et al. also teach antibodies that bind the polypeptide (paragraphs [0592] +). Ruben et al. specifically suggest monoclonal, humanized, labeled and fragment antibodies (paragraph [0603]).

Art Unit: 1646

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth C. Kemmerer, Ph.D., whose telephone number is (571) 272-0874. The examiner can normally be reached Monday through Thursday from 7:00 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached on (571) 272-0871.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ECK

ELIZABETH KEMMERER PRIMARY EXAMINER

Elyabek C. Kennew